<scp>CD15</scp><sup>+</sup> tumor infiltrating granulocytic cells can predict recurrence and their depletion is accompanied by good responses to S‐1 with oral cancer

Seki‐Soda, Mai; Sano, Takaaki; Ogawa, Masaru; Yokoo, Satoshi; Oyama, Tetsunari

doi:10.1002/hed.26712

Cited by 6 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD15+ MDSC is present in the tissue of oral cancer. Immunohistochemistry analysis of biopsy and resected specimens proved that decreasing its number due to preoperative chemotherapy can improve the prognosis [94].…”

Section: Experimental Medicine Involving Cd15mentioning

confidence: 99%

CD15 and CD15s in The Anticancer Therapy

Szlasa¹,

Wilk²,

Knecht-Gurwin³

et al. 2022

Preprint

View full text Add to dashboard Cite

CD15 (Lewis X/Lex) is a fucosyl (3-fucosly-N-acetyl-lactosamine) moiety found on membrane proteins of various cancer cells. These include renal cancer, prostate and bladder cancers, acute leukemias, hepatocellular carcinoma, breast cancer and melanoma. The antigen plays an espe-cially significant role in renal cell carcinoma. Its high expression serves as a good prognostic marker for patients and high hopes are related to its use in the immunotherapy of the tumor. The biological role of CD15 is the interaction with E-, L- and P-selectins (adhesion molecules) and al-lowing for the adhesion with the endothelial cells. In this way, cancer cells start to interact with the endothelium of blood vessels and consequently move out from the blood flow to the sur-rounding tissues. The blockage of antigen’s function results in reduced metastatic potential. Moreover, the molecule may be a therapeutic target against cancer in monoclonal antibod-ies-based therapies. CD15s is a sialyl derivative of CD15, that possess its own unique characteris-tics. Unlike high expression of CD15, which is a prognostic factor in Hodgkin lymphoma, CD15s relate to poor prognosis for the patients. Due to the high abundance in cancer cells, CD15 is con-sidered as a marker of Cancer Stem Cells. This review presents a comprehensive description of the role of CD15 and CD15s in cancer development and metastasis and overviews the clinical appli-cations of the anti-CD15 therapy.

show abstract

Section: Experimental Medicine Involving Cd15mentioning

confidence: 99%

CD15 and CD15s in The Anticancer Therapy

Szlasa¹,

Wilk²,

Knecht-Gurwin³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Overall, the studies report on a total of 920 patients (range 21–161), with studies coming from Europe ( n = 6, 40%) [ 30 , 31 , 32 , 33 , 34 , 35 ], China ( n = 3, 20%) [ 36 , 37 , 38 ], Japan ( n = 3, 20%) [ 39 , 40 , 41 ], Korea ( n = 2, 13%) [ 42 , 43 ], and the USA ( n = 1, 7%) [ 44 ]. The studies were published in the time range 2017–2021, with the vast majority appearing in the years 2020 and 2021.…”

Section: Resultsmentioning

confidence: 99%

“…The study of So et al reported on the effect of radiotherapy, even though there was a minor quota of patients also treated with chemotherapy, and showed a decrease in PD-L1 expression in 69% of cases, with negativization in 23% [ 43 ]. In one study, the effect of a precursor of fluorouracil alone was investigated and the authors reported a significant decrease in PD-L1 expression in tumor cells [ 41 ], while the other studies where fluorouracil was deployed reported, on the contrary, an increase in the quota of positive cases [ 34 , 42 ]. In these studies, however, fluorouracil was used in combination with a platinum agent and docetaxel, and results were not stratified for different combinations of chemotherapy or cisplatin-based therapy separately.…”

Section: Discussionmentioning

confidence: 99%

Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma

Girolami

Marletta

Fiorentino

et al. 2023

JPM

View full text Add to dashboard Cite

Background: Programmed death-ligand 1 (PD-L1) checkpoint inhibitors represent a mainstay of therapy in head and neck squamous cell cancer (HNSCC). However, little is known about the influence of combined therapy on PD-L1 expression. The study aims to gather evidence on this topic. Methods: A systematic search was carried out in electronic databases Pubmed-MEDLINE and Embase to retrieve studies on the comparison of PD-L1 expression before and after conventional therapy. Data were extracted and a quantitative analysis with pooled odds ratios (ORs) was performed when applicable. Results: Of 5688 items, 15 were finally included. Only a minority of studies assessed PD-L1 with the recommended combined positive score (CPS). The results are highly heterogeneous, with some studies reporting an increase in PD-L1 expression and others reporting a decrease. Three studies allowed for quantitative analysis and showed a pooled OR of 0.49 (CI 0.27–0.90). Conclusions: From the present evidence, a clear conclusion towards an increase or decrease in PD-L1 expression after combined therapy cannot be drawn, but even with few studies available, a trend towards an increase in expression in tumor cells at a cutoff of 1% can be noted in patients undergoing platinum-based therapy. Future studies will provide more robust data on the effect of combined therapy on PD-L1 expression.

show abstract

“…CD15 + MDSCs are present in oral cancer tissues. Immunohistochemistry analysis of biopsy and resected specimens proved that decreasing their numbers with preoperative chemotherapy can improve prognoses [33]. Several factors regulate the functioning of MDSCs.…”

Section: Role Of Cd15 and Cd15s In Neoplasmsmentioning

confidence: 99%

Prognostic and Therapeutic Role of CD15 and CD15s in Cancer

Szlasa

Wilk

Knecht-Gurwin

et al. 2022

Cancers

View full text Add to dashboard Cite

CD15 (Lewis X/Lex) is a fucosyl (3-fucosly-N-acetyl-lactosamine) moiety found on membrane proteins of various cancer cells. These cancers include renal cancer, prostate and bladder cancers, acute leukaemias, hepatocellular carcinoma, breast cancer and melanoma. The biological role of CD15 is interaction with E-, L- and P-selectins (adhesion molecules), allowing for adhesion with endothelial cells. In this way, cancer cells start to interact with the endothelia of blood vessels and consequently move out from the blood flow to the surrounding tissues. Blockage of the antigen’s function results in reduced metastatic potential. Moreover, the molecule may be a therapeutic target against cancer in monoclonal antibody-based therapies. CD15 may serve as a prognostic marker for patients and there are high hopes for its use in the immunotherapeutic treatment of tumours. CD15s is a sialyl derivative of CD15 that possesses its own unique characteristics. Its soluble form may act as a competitive inhibitor of the interaction of cancer cells with epithelial cells and thus disallow migration through the vessels. However, the prognostic relevance of CD15 and CD15s expression is very complex. This review presents a comprehensive description of the role of CD15 and CD15s in cancer development and metastasis and overviews its significance for clinical applications.

show abstract

CD15⁺ tumor infiltrating granulocytic cells can predict recurrence and their depletion is accompanied by good responses to S‐1 with oral cancer

Cited by 6 publications

References 41 publications

CD15 and CD15s in The Anticancer Therapy

CD15 and CD15s in The Anticancer Therapy

Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma

Prognostic and Therapeutic Role of CD15 and CD15s in Cancer

Contact Info

Product

Resources

About

CD15+ tumor infiltrating granulocytic cells can predict recurrence and their depletion is accompanied by good responses to S‐1 with oral cancer

Cited by 6 publications

References 41 publications

CD15 and CD15s in The Anticancer Therapy

CD15 and CD15s in The Anticancer Therapy

Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma

Prognostic and Therapeutic Role of CD15 and CD15s in Cancer

Contact Info

Product

Resources

About

CD15⁺ tumor infiltrating granulocytic cells can predict recurrence and their depletion is accompanied by good responses to S‐1 with oral cancer